Ribociclib (Kisqali, Novartis) 'in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist'.
The dosage schedule is available in the summary of product characteristics for ribociclib.
The list prices of ribociclib 200-mg tablets are:
£983.33 per 21-pack
£1,966.67 per 42-pack
£2,950.00 per 63-pack
(excluding VAT; BNF online, accessed March 2025).
The company has a simple patient access scheme. This makes ribociclib available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, Novartis did not disclose its Carbon Reduction Plan for UK carbon emissions.